Passage Bio, Inc.

Informe acción NasdaqGS:PASG

Capitalización de mercado: US$29.8m

Passage Bio Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Passage Bio de 30.3% y 88.2% respectivamente, mientras que el BPA crecerá en un 50.2% al año.

Información clave

30.3%

Tasa de crecimiento de los beneficios

50.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs28.3%
Tasa de crecimiento de los ingresos88.2%
Rentabilidad financiera futuran/a
Cobertura de analistas

Low

Última actualización14 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Sep 24
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Jun 11
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Feb 27
We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Nov 13
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully

Jun 23
We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Nov 13
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage appoints William Chou CEO

Oct 10

Passage Bio GAAP EPS of -$0.73 beats by $0.09

Aug 04

We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Jun 03
We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Passage Bio: Worth Keeping An Eye On

Apr 11

Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Dec 15
Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans

Aug 19
Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans

Passage Bio: Price Reduced, But Without Data, Does Not Look Convincing

Jun 06

Passage Bio partners with InformedDNA to offer counseling, testing for early dementia

May 03

We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely

Mar 08
We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely

Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?

Feb 01
Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?

Passage Bio on go with PBGM01 gene therapy trial in the U.S.

Jan 04

Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares

Dec 28
Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares

U.K. authorizes Passage Bio's PBGM01 trial

Dec 10

Passage Bio (PASG) Investor Presentation - Slideshow

Nov 16

Passage Bio EPS beats by $0.13

Nov 10

Passage Bio’s PBKR03 nabs Orphan drug tag and accelerated review status for Krabbe disease

Oct 28

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:PASG - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/2026N/A-75N/AN/A4
12/31/2025N/A-68N/AN/A5
12/31/2024N/A-68N/AN/A5
9/30/2024N/A-69N/AN/AN/A
6/30/2024N/A-77-71-71N/A
3/31/2024N/A-84-75-75N/A
12/31/2023N/A-102-78-78N/A
9/30/2023N/A-112-83-83N/A
6/30/2023N/A-112-89-87N/A
3/31/2023N/A-128-99-96N/A
12/31/2022N/A-136-123-118N/A
9/30/2022N/A-160-137-125N/A
6/30/2022N/A-180-165-143N/A
3/31/2022N/A-189-167-141N/A
12/31/2021N/A-185-153-127N/A
9/30/2021N/A-173-145-126N/A
6/30/2021N/A-155-110-102N/A
3/31/2021N/A-134-92-89N/A
12/31/2020N/A-112-82-81N/A
9/30/2020N/A-86-69-69N/A
6/30/2020N/A-69-63-62N/A
3/31/2020N/A-56-62-62N/A
12/31/2019N/A-46-42-40N/A
9/30/2019N/A-38-45-41N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que PASG siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que PASG siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que PASG siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que PASG no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que PASG no tenga ingresos el año que viene.


Previsiones de crecimiento de los beneficios por acción


Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PASG se prevé que sea elevada dentro de 3 años.


Descubre empresas en crecimiento